U.S. Markets closed
  • S&P 500

    4,704.54
    +15.87 (+0.34%)
     
  • Dow 30

    35,870.95
    -60.10 (-0.17%)
     
  • Nasdaq

    15,993.71
    +72.14 (+0.45%)
     
  • Russell 2000

    2,363.59
    -13.42 (-0.56%)
     
  • Gold

    1,861.20
    -0.20 (-0.01%)
     
  • Silver

    24.88
    -0.02 (-0.08%)
     
  • EUR/USD

    1.1369
    -0.0006 (-0.0568%)
     
  • 10-Yr Bond

    1.5890
    -0.0150 (-0.94%)
     
  • Vix

    17.59
    +0.48 (+2.81%)
     
  • GBP/USD

    1.3497
    -0.0003 (-0.0216%)
     
  • USD/JPY

    114.3040
    +0.0520 (+0.0455%)
     
  • BTC-USD

    54,384.39
    -3,232.53 (-5.61%)
     
  • CMC Crypto 200

    1,402.14
    -65.80 (-4.48%)
     
  • FTSE 100

    7,255.96
    -35.24 (-0.48%)
     
  • Nikkei 225

    29,683.09
    +84.43 (+0.29%)
     

FDA Panel Backs Pfizer’s Covid Vaccine for Children 5 to 11

·6 min read
FDA Panel Backs Pfizer’s Covid Vaccine for Children 5 to 11
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

The Food and Drug Administration’s vaccines advisory committee on Tuesday voted overwhelmingly in favor of an emergency use authorization for Pfizer ‘s Covid-19 vaccine for children aged 5 to 11, though committee members raised concerns about the risk of side effects, and some said that only high-risk children should receive the vaccine. One committee member, Dr. Cody Meissner, speaking directly after the vote, said that he hoped that the vaccines advisory committee to the Centers for Disease Control and Prevention, which will consider the vaccine next week, would limit its recommendation to children with additional risk factors.